
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical Inc. is expected to experience significant financial growth, with projected EBITDA increasing from $24.4 million in FY26 (16.8% margin) to $27.3 million in FY27 (19.1% margin), demonstrating an improvement in operational efficiency. Additionally, the company has achieved positive free cash flow (FCF) in the most recent quarter, with projections forecasting an increase from $5.1 million in FY26 to $6.0 million in FY27. This combination of expanding margins and positive cash flow underscores a favorable outlook for Lifecore Biomedical's financial performance.
Bears say
Lifecore Biomedical Inc. exhibits a concerning financial outlook, primarily due to its high leverage ratio and the expectation of minimal revenue growth until calendar year 2027. Although a market growth figure of 10% for fill/finish services is considered reasonable, the actual growth is anticipated to be lower, particularly with the inclusion of small molecule injectables. These factors contribute to a justification for Lifecore's valuation discount compared to its peers in the contract development and manufacturing sector.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares